Overview

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Status:
Not yet recruiting

Trial end date:
2027-10-07

Target enrollment:

Participant gender:

Summary

This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Amivantamab-vmjw
Osimertinib